Lancashire and South Cumbria
Formulary
Formulary
11 Eye
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
11-11 Other
| Holoclar |
|
Formulary
|
79,000 - 316,000 cells/cm2 living tissue equivalent |
 NICE TA467: Holoclar for treating limbal stem cell deficiency after eye burns |
|
| Voretigene neparvovex Luxturna® |
|
Formulary
|
Tertiary Centre only |
|
NICE: Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations |
|
|
Links
LSCMMG: Gastroenterology Biologics Pathway- LSCMMG: Primary Care Constipation Guidelines
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE HST11: Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people
- NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
- NICE TA467: Holoclar for treating limbal stem cell deficiency after eye burns
- NICE TA467: Holoclar for treating limbal stem cell deficiency after eye burns
- NICE TA532: Cenegermin for treating neurotrophic keratitis
- NICE: Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations
- TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears